KEPZEMRY

EUIPO EUIPO 2021 Trademark registered

Protect this trademark from copycats!

With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.

The Union trademark KEPZEMRY was filed as Word mark on 08/18/2021 at the European Union Intellectual Property Office.
It was registered as a trademark on 02/15/2022. The current status of the mark is "Trademark registered".

Trademark Details Last update: February 8, 2024

Trademark form Word mark
File reference 018536160
Application date August 18, 2021
Publication date November 8, 2021
Entry date February 15, 2022
Expiration date August 18, 2031

Trademark owner

Lilly Corporate Center
46285 Indianapolis,
US

Trademark representatives

Widenmayerstr. 10 80538 München DE

goods and services

5 Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment, prevention and/or diagnosis of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease; Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment, prevention and/or diagnosis of dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders; Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment, prevention and/or diagnosis of lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and vascular diseases; Diagnostic agents, preparations and substances for medical purposes; diagnostic scanning agents for medical use, namely, diagnostic scanning agents for in vivo use; radiopharmaceutical diagnostic preparations for medical use; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative amyloid diseases; pharmaceutical preparations

ID: 11018536160